Key result
Angiotensin-converting enzyme (ACE) inhibitors provide cardioprotective benefits including improved perfusion, diminished cardiac work, and decreased morbidity and mortality in congestive heart failure.
ACE inhibitors offer broad cardioprotective effects beyond blood pressure lowering, improving outcomes in ischemic heart disease and heart failure.
Supports ACE inhibitor use in heart failure; confirms benefits in prior data but leaves open questions on modern regimens.
Antihypertensive drugs have various effects, both positive and negative, on metabolic and hemodynamic risk factors for coronary artery disease. Cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitors have recently been described. The benefits of ACE inhibition include not only a reduction in blood pressure but also improved insulin responsiveness, prevention of potassium loss, diminished myocardial oxygen demand, suppression of catecholamines, and interaction with bradykinin and prostaglandins. These benefits result in improved perfusion of vital organs, diminished cardiac work, and protection of coronary vessels, evident in improved left ventricular systolic and diastolic function, elevation of the anginal threshold in ischemic heart disease, and decreased morbidity and mortality in congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Haralambos Gavras (1991) conducted a review in Coronary artery disease, ischemic heart disease, congestive heart failure. Angiotensin-converting enzyme (ACE) inhibitors was evaluated. Angiotensin-converting enzyme (ACE) inhibitors provide cardioprotective benefits including improved perfusion, diminished cardiac work, and decreased morbidity and mortality in congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: